Scientists leading an international consortium have developed light-activated experimental eye drops that restored vision in blind mice without requiring gene therapy or implants.
The study demonstrated that simple eye drops containing light-sensitive chemical compounds enabled blind rodents to detect light and alter their behavior accordingly under normal indoor lighting conditions.
The research, published in the Journal of the American Chemical Society, focused on a newly developed family of molecules named prosthe6. Created using photopharmacology, a technique that uses light to reversibly switch drug activity on and off, the molecules take over the job of damaged photoreceptors in the eye.
In degenerative eye conditions such as age-related macular degeneration and retinitis pigmentosa, light-detecting cells known as photoreceptors gradually deteriorate and die. However, much of the underlying neural circuit in the deeper layers of the retina, including specialized nerve cells called ON-bipolar cells, remains intact.
The prosthe6 compounds were specifically engineered to act on these ON-bipolar cells, which normally receive nerve signals directly from photoreceptors. When modified by light, the molecules activate signals within the retina and restart the visual process that normally begins when photoreceptors detect illumination.
Targeting Retinal Neurons With Light
Pau Gorostiza, a research professor at the Institute for Bioengineering of Catalonia who led the study, explained that the molecules do not cure blindness because they do not address the root cause of photoreceptor degeneration.
However, Gorostiza noted that the compounds are remarkably effective at restoring visual function through a simple approach that could prove comfortable and convenient for patients.
The Institute for Bioengineering of Catalonia, based in Barcelona, Spain, specializes in bioengineering and multidisciplinary medical research. Photopharmacology has emerged in recent years as an innovative branch of pharmacology, allowing scientists to use targeted light exposure to control the location, timing, and intensity of a drug's therapeutic effects inside living tissue.
Before testing the molecules in rodents, the research team conducted preliminary experiments on blind zebrafish larvae. When treated with the light-sensitive compounds, the larvae successfully recovered eye movements associated with natural visual responses.
Restoring Light Sensitivity in Animal Models
The researchers then tested the therapy across animal models of age-related macular degeneration and retinitis pigmentosa in mice. Healthy mice spontaneously prefer dark spaces and instinctively avoid brightly lit areas, a natural behavior that disappears when animals lose their vision.
After receiving the prosthe6 treatment, the blind mice resumed showing a clear preference for dark environments. According to the researchers, this behavioral change indicated that the animals could detect ambient light and use the information to orient themselves without needing any prior training.
The visual recovery was achieved under light levels comparable to typical indoor illumination or an overcast day outdoors. Among the tested molecules, two specific variants named prosthe6-12 and prosthe6-15 produced especially promising results.
The therapeutic effects were observed both after a direct injection into the eye and following topical application of the substances as eye drops.
An Alternative to Invasive Eye Therapies
The researchers described the synthetic molecules as molecular prostheses because they allow the retina to respond to light again without relying on implanted electronic devices or genetic modifications.
The approach offers potential advantages over existing treatments for severe retinal degeneration, which face significant practical limitations. Gene therapy is only suitable for a small fraction of patients who carry specific gene mutations, while electronic retinal prostheses can be highly invasive, expensive, and require lengthy patient training.
Retinitis pigmentosa encompasses a group of rare genetic eye disorders that cause progressive vision loss, whereas age-related macular degeneration affects millions worldwide as a leading cause of sight loss in older adults. Both conditions damage photoreceptor cells while leaving deeper retinal cell layers operational for extended periods, providing a target window for molecular intervention.
The research remains at an experimental stage. The research team is currently evaluating the safety profile and drug formulation of the compounds to extend the duration of visual function recovery following each dose.
Gorostiza acknowledged that turning the experimental compounds into an approved clinical therapy will be a long and laborious process. However, he emphasized that the study proves a realistic possibility of restoring high-quality vision non-invasively and reversibly through pharmaceutical treatment.
